Due to the structure of acylhydrazones both by the pharmacophore–CO–NH–N= group and
by the different substituents present in the molecules of compounds of this class, various …

Pulmonary arterial hypertension (PAH) is a life‐threatening disease characterized by
increased pulmonary arterial pressure and pulmonary vascular resistance, which result in …

Background Experimental research has reported beneficial effects of mesenchymal stromal
cell (MSC) therapy in pulmonary arterial hypertension (PAH). However, these studies either …

Background Monocrotaline has been widely used to establish an animal model of
pulmonary hypertension. The molecular target underlying monocrotaline‐induced …

Background This work evaluated the hypothesis that 3, 4-methylenedioxybenzoyl-2-
thienylhydrazone (LASSBio-294), an agonist of adenosine A2A receptor, could be beneficial …

For the first time, the present study unravels a cardiospecific therapeutic approach for
Pulmonary Arterial Hypertension (PAH), a disease with a very poor prognosis and high …

Rationale Pulmonary hypertension (PH) is characterized by pulmonary vascular remodeling
that leads to pulmonary congestion, uncompensated right-ventricle (RV) failure, and …

Pulmonary arterial hypertension (PAH) is a clinical condition characterized by pulmonary
arterial remodeling and vasoconstriction, which promote chronic vessel obstruction and …

Background Pulmonary arterial hypertension (PAH) is a devastating disease that lacks
sufficient treatment. Studies have shown that the Nod-like receptor family, pyrin domain …

Background: Right-sided heart failure has high morbidity and mortality, and may be caused
by pulmonary arterial hypertension. Fractal dimension is a differentiated and innovative …